Co-diagnostics, inc. awarded funding for co-dx pcr home platform from nih radx® tech program

The company intends to use the funds awarded by the national institutes of health for completion of its upper respiratory panel multiplex on co-dx pcr home™ platform salt lake city , july 13, 2023 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company" or "co-dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has been awarded $1.2 million in funding from the national institutes of health (nih) as part of the rapid acceleration of diagnostics (radx®) tech program for completion of its upcoming upper respiratory panel on the company's co-dx pcr home™ testing platform. co-diagnostics will utilize the funds from the radx tech award to complete development of its flu a/b, covid-19, and rsv multiplex test, preparatory for that test to begin clinical trials on the co-dx pcr home.
CODX Ratings Summary
CODX Quant Ranking